Product Information
LOMAIRA 8 MG TABLET is a generic product labeled by KVK-Tech Inc., priced at $0.6370 per EA under NDC 10702000109. Its NADAC has been published 227 times since Jul 20, 2022.
FDA first approved this application on Sep 12, 2016. Its Orange Book therapeutic-equivalence code is AA.
Strength
8 mg/1
Manufacturer
KVK-Tech Inc.NDC
10702000109
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
11/18/2026
Active Ingredients
PHENTERMINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA203495FDA Approved
9/12/2016
TE Code
AA
On Market Since
9/12/2016
Pharmacological Classes
Price Statistics
The NADAC for LOMAIRA 8 MG TABLET has been published 227 times since Jul 20, 2022, and over the history we have for it it has risen 23.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6370 per EA |
|---|---|
| All-time high | $0.6370 (Nov 18, 2026) |
| All-time low | $0.5119 (Jan 18, 2023) |
| 52-week high | $0.6370 |
| 52-week low | $0.6139 |
| Median price | $0.5659 |
| Average price | $0.5710 |
| Largest weekly change | +6.9% (Apr 19, 2023) |
| Weeks tracked | 227 |
| Tracking since | Jul 20, 2022 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
KVK-Tech Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Phentermine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sympathomimetic Amine Anorectic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LOMAIRA 8 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LOMAIRA 8 MG TABLET, manufactured by KVK-Tech Inc., is $0.6370 per EA (NDC 10702000109), effective Nov 18, 2026.
How has the price of LOMAIRA 8 MG TABLET changed over time?
Over the history we have for it, the NADAC for LOMAIRA 8 MG TABLET has risen 23.7%. It has been tracked across 227 weekly CMS publications since Jul 20, 2022.
What are the highest and lowest recorded NADAC prices for LOMAIRA 8 MG TABLET?
Since Jul 20, 2022, the NADAC for LOMAIRA 8 MG TABLET has ranged from a low of $0.5119 (Jan 18, 2023) to a high of $0.6370 (Nov 18, 2026), with a median of $0.5659 per EA.
Are there cheaper alternatives to LOMAIRA 8 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as LOMAIRA 8 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures LOMAIRA 8 MG TABLET?
LOMAIRA 8 MG TABLET (NDC 10702000109) is labeled by KVK-Tech Inc., and CMS classifies it as a generic product.